<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1244">
  <stage>Registered</stage>
  <submitdate>14/07/2006</submitdate>
  <approvaldate>14/07/2006</approvaldate>
  <nctid>NCT00358566</nctid>
  <trial_identification>
    <studytitle>GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer</studytitle>
    <scientifictitle>"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Eudract no. 2005-005014-21</secondaryid>
    <secondaryid>PX115.1.1-302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Unresectable Pancreatic Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - GV1001
Treatment: drugs - Gemcitabine (Chemotherapy)

Active Comparator: Gemcitabine - Gemcitabine alone treatment.

Experimental: GV1001 - GV1001 in sequential combination with Gemcitabine


Other interventions: GV1001
0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.

Treatment: drugs: Gemcitabine (Chemotherapy)
Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival time</outcome>
      <timepoint>12 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>Time of progression</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Histologically or cytologically confirmed, unresectable, locally advanced, or
             metastatic adenocarcinoma of the pancreas.

          2. Adequate hematological parameters:

             Hemoglobin &gt;/= 9.5 g/dL [SI units, 5.9 mmol/L] WBC &gt;/= 3000/mm3 [SI units, &gt;/= 3 x
             109/L] Platelets &gt;/= 100,000/mm3 [SI units, &gt;/= 100 x 109/L]

          3. Adequate baseline liver function:

             Total Bilirubin &lt; 3x ULN and

             Without liver metastases:

             AST (SGOT) &lt;/= 2.5 x ULN ALT (SGPT) &lt;/= 2.5 x ULN

             With liver metastases:

             AST (SGOT) &lt;/= 5 x ULN ALT (SGPT) &lt;/= 5 x ULN

          4. Serum creatinine &lt;/= 1.5 mg/dL [SI units, 132 Âµmol/L].

          5. Performance status ECOG 0-1.

          6. Male or female 18 - 75 years inclusive.

          7. Minimum life expectancy of 3 months.

          8. Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Treatment with chemotherapy for pancreatic cancer.

          2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion

          3. Immune-suppressive therapy &lt;4 weeks prior to inclusion

          4. Chronic corticosteroid use except for asthma inhalers / topical use

          5. Radiotherapy within 8 weeks of randomisation.

          6. Other prior malignancies except for adequately treated non-melanoma skin cancers (BCC,
             SCC) and carcinoma in situ of the cervix.

          7. Known diagnosis of HIV (AIDS), Hepatitis B, C.

          8. Known history of or co-existing autoimmune disease.

          9. Known CNS metastases.

         10. Clinically significant serious disease or organ system disease not currently
             controlled on present therapy.

         11. Pregnancy or lactation.

         12. Women of childbearing potential not using reliable and adequate contraceptive methods*

         13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.

         14. Unable for any other reason to comply with the protocol (treatment or assessments).

               -  Adequate contraceptive methods are defined as the use of oral, implanted,
                  injectable, mechanical or barrier products for the prevention of pregnancy; or
                  women who are practising abstinence; or where the partner is sterile, for example
                  a vasectomy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>360</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2008</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>St George Hospital, Department of Medical Oncology - Kogarah</hospital>
    <hospital>Westmead Hospital, Dept. of Medical Oncology and Palliative Care - Westmead</hospital>
    <hospital>The Townsville Hospital, Townsville Cancer Centre - Douglas</hospital>
    <hospital>Flinders Medical Centre, Medical Oncology - Clinical Trials - Bedford Park</hospital>
    <hospital>Dept. of Clinical Haematology / Oncology,the Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Royal Hobart Hospital, Centre for Clinical Research - Hobart</hospital>
    <hospital>Box Hill Hospital, ECRU Oncology - Box Hill</hospital>
    <hospital>The Alfred Hospital, Medical Oncology Unit - Melbourne</hospital>
    <hospital>Fremantle Hospital, Haemtology Department - Fremantle</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Mount Medical Centre, Perth Oncology - Perth</hospital>
    <hospital>Royal Perth Hospital, Department of Medical Oncology - Perth</hospital>
    <hospital>Wesley Research Institute Limited - Auchenflower Qld</hospital>
    <postcode>NSW 2217 - Kogarah</postcode>
    <postcode>NSW 2145 - Westmead</postcode>
    <postcode>QLD 4814 - Douglas</postcode>
    <postcode>SA 5042 - Bedford Park</postcode>
    <postcode> - Woodville South</postcode>
    <postcode>TAS 7000 - Hobart</postcode>
    <postcode>VIC 3128 - Box Hill</postcode>
    <postcode>VIC 3004 - Melbourne</postcode>
    <postcode>WA 6160 - Fremantle</postcode>
    <postcode> - Nedlands</postcode>
    <postcode>WA 6000 - Perth</postcode>
    <postcode> - Auchenflower Qld</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Ãrhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers Cedex 01</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Evreux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lorient</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Moreau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Brieuc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Gregoire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ancona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catanzaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Kristiansand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Tromsoe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Elblag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>MalmÃ¶</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmexa A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>ICON Clinical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>ORION Clinical Services</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>CIRION Central Laboratory</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Dorevitch</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>INC Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally
      advanced and metastatic adenocarcinoma of the pancreas.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00358566</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ask Aabenhus, MSc. (Pharm)</name>
      <address>Pharmexa A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>